SELLAS Life Sciences Falls 18%: Leukemia Trial Data Due This Quarter

NEW YORK, October 28 —

SELLAS Life Sciences Group, Inc. (SLS) fell 18% when its REGAL Phase 3 leukemia trial logged its 80th death, triggering the mandatory final analysis.

The 80th Death Was Baked Into the Protocol

The market's reaction deserves scrutiny. REGAL was designed with 80 deaths as the pre-specified event count: not a safety signal, not an early-futility stop, not a surprise. The trial simply reached its own built-in finish line. What the selloff actually priced was the closing of the uncertainty window. Once the trigger fires, results are weeks rather than months away, and investors who hold biotech for options value tend to exit before the coin lands.

Seeking Alpha's headline "The Longer The Wait, The More Likely A REGAL Failure" captures a real concern: extended event accumulation in acute myeloid leukemia trials can correlate with compressed survival differences between arms. Whether the market has accurately priced that risk is the question this quarter will answer.

26.7% Short Interest Means the Readout Cuts Both Ways

More than a quarter of SLS's float is sold short. That is the angle most wire coverage is burying. That gap-down visible in the chart reflects sellers pricing in failure, but a positive overall survival result would not just reward long holders. It would force a substantial short cover into thin post-catalyst liquidity, and the gap-down could reverse sharply.

Binary catalysts in small-cap biotech rarely land softly. The distribution of outcomes here is bimodal: the stock likely ends up well above or well below $10.38, not somewhere in between.

No FCF, No Floor If REGAL Misses

SLS generates -$16mn in annual free cash flow with a trailing EPS of -$0.21. There is no product revenue to cushion a negative readout, no independent pipeline asset that floors the valuation on its own. Investors modeling the scenario tree can use the DCF calculator to stress-test what a post-approval SLS would need to earn to justify current prices. At -103.8x forward P/E, the multiple is not a valuation. It is a placeholder for an outcome that has not been priced.

If REGAL misses its overall survival endpoint, the conversation shifts from "what is this worth" to "how long can it fund operations." That is a materially different question.

Overall Survival Is the Hard Bar. One Number Proves the Bull Case Wrong.

Preliminary results are expected this quarter. The primary endpoint is overall survival, not a surrogate marker like progression-free survival. Watch for the confidence interval around the hazard ratio: a result above 1.0 at the pre-specified significance threshold would confirm the investigational therapy did not extend life. That single number, when it prints, either validates or destroys the current setup. It will not do anything in between.

For a full deep-dive on SLS's trial design, scenario tree, and valuation framework, Basis Report has published a research report with a BUY rating that walks through each outcome in detail.

Current fundamentals, valuation and filing history for SELLAS Life Sciences Group, Inc. (SLS) are tracked on its Basis Report page.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.